These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24644264)

  • 1. Tumor cell-expressed SerpinB2 is present on microparticles and inhibits metastasis.
    Schroder WA; Major LD; Le TT; Gardner J; Sweet MJ; Janciauskiene S; Suhrbier A
    Cancer Med; 2014 Jun; 3(3):500-13. PubMed ID: 24644264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deficiency of plasminogen activator inhibitor-2 results in accelerated tumor growth.
    Westrick RJ; Røjkjaer LP; Yang AY; Roh MH; Siebert AE; Ginsburg D
    J Thromb Haemost; 2020 Nov; 18(11):2968-2975. PubMed ID: 32780555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SerpinB2 inhibits migration and promotes a resolution phase signature in large peritoneal macrophages.
    Schroder WA; Hirata TD; Le TT; Gardner J; Boyle GM; Ellis J; Nakayama E; Pathirana D; Nakaya HI; Suhrbier A
    Sci Rep; 2019 Aug; 9(1):12421. PubMed ID: 31455834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.
    Bae SY; Park HJ; Hong JY; Lee HJ; Lee SK
    Sci Rep; 2016 Aug; 6():32258. PubMed ID: 27558531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A physiological function of inflammation-associated SerpinB2 is regulation of adaptive immunity.
    Schroder WA; Le TT; Major L; Street S; Gardner J; Lambley E; Markey K; MacDonald KP; Fish RJ; Thomas R; Suhrbier A
    J Immunol; 2010 Mar; 184(5):2663-70. PubMed ID: 20130210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer.
    Cochran BJ; Croucher DR; Lobov S; Saunders DN; Ranson M
    J Biol Chem; 2011 Jul; 286(27):24467-75. PubMed ID: 21606492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The serine protease inhibitor serpinB2 binds and stabilizes p21 in senescent cells.
    Hsieh HH; Chen YC; Jhan JR; Lin JJ
    J Cell Sci; 2017 Oct; 130(19):3272-3281. PubMed ID: 28794016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of SerpinB2 in immunity.
    Schroder WA; Major L; Suhrbier A
    Crit Rev Immunol; 2011; 31(1):15-30. PubMed ID: 21395508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
    Foca C; Moses EK; Quinn MA; Rice GE
    Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
    Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
    Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
    van Dam PA; Coelho A; Rolfo C
    Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA-200c/141 upregulates SerpinB2 to promote breast cancer cell metastasis and reduce patient survival.
    Jin T; Suk Kim H; Ki Choi S; Hye Hwang E; Woo J; Suk Ryu H; Kim K; Moon A; Kyung Moon W
    Oncotarget; 2017 May; 8(20):32769-32782. PubMed ID: 28427146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma.
    Eitzman DT; Krauss JC; Shen T; Cui J; Ginsburg
    Blood; 1996 Jun; 87(11):4718-22. PubMed ID: 8639841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human papilloma virus transformed CaSki cells constitutively express high levels of functional SerpinB2.
    Major L; Schroder WA; Gardner J; Fish RJ; Suhrbier A
    Exp Cell Res; 2011 Feb; 317(3):338-47. PubMed ID: 20974129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.
    Kasyapa CS; Kunapuli P; Hawthorn L; Cowell JK
    Blood; 2006 May; 107(9):3693-9. PubMed ID: 16410451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of tumor cell-induced extracellular matrix degradation--inhibition of cell-surface proteolytic activity might have a therapeutic effect on tumor cell invasion and metastasis].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1996 Aug; 48(8):623-32. PubMed ID: 8808830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
    Zhang W; Ling D; Tan J; Zhang J; Li L
    Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation.
    Quax PH; van Muijen GN; Weening-Verhoeff EJ; Lund LR; Danø K; Ruiter DJ; Verheijen JH
    J Cell Biol; 1991 Oct; 115(1):191-9. PubMed ID: 1918136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2.
    Laug WE; Cao XR; Yu YB; Shimada H; Kruithof EK
    Cancer Res; 1993 Dec; 53(24):6051-7. PubMed ID: 8261421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.